Lung Therapeutics, Inc. is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a
Andrew MazarFounder and Head of Product DevelopmentDr. Mazar serves as Head of Product Development in addition to his current position as Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence at Northwestern University.Prior to this, Dr. Mazar was most recently the Chief Scientific Officer at Attenuon, LLC and has led three projects at Attenuon through IND and into phase II trials.He is currently managing an additional three projects at various stages of IND enabling development.
Prior to Attenuon, Dr. Mazar had significant input in three projects that led two successful INDs, two of which made it through phase II trials and one of which is currently in phase II trials.
One of these projects was the original development of scuPA for the treatment of myocardial infarction.
Thus, Dr. Mazar has extensive expertise in translating early stage science into clinical projects through phase II clinical development and managing this entire process.
He also has direct experience in the development of LTI-01 (scuPA) as a clinical therapeutic agent.
During his tenure in biotechnology, Dr. Mazar has led several projects that culminated in several out-license deals as well as funded collaborations.
A new partnership deal with a large European venture group on all of Attenuon's projects has closed.
During the partnership process, Dr. Mazar led early and late stage discussion with most every large and mid-size biotechnology company interested in cancer therapeutics.
During these discussions, terms sheets were obtained from five different suitors, all of them public companies.
While at Attenuon, Dr. Mazar managed $63M of investment capital, the majority of this raised through a single investor, during his nine year tenure and led a road show managed by Bank of America.
Andrew P. Mazar, Ph.D., Lung Therapeutics' Co-Founder and Consulting Head of Product Development, said, "Having consulted on other EU orphan drug submissions in the past, I know how challenging the process can be.
Co-Founder and Chief Scientific OfficerDr. Mazar has spent twenty five years working on drug discovery and development at the interface of academia and industry and has founded or co-founded eight start-up companies to commercialize new drug discoveries.
He is also internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis as well as basic mechanisms of cancer metastasis.
He is the co-author of 99 peer reviewed publications and 16 reviews and book chapters.
Prior to co-founding Tactic Pharmaceuticals in 2010 and joining the Chemistry of Life Processes Institute at Northwestern University in 2009, Dr. Mazar was the Chief Scientific Officer at Attenuon, LLC in San Diego from 2000 to 2009 and led discovery and development efforts resulting in three drugs entering oncology clinical trials.Dr. Mazar has now overseen 11 IND enabling efforts, many of these focused on drugs discovered in academia.
Dr. Mazar is recognized internationally for his work on the urokinase plasminogen activator (uPA) system and its role in tumor progression.
In addition to his research work on the uPA system, Dr. Mazar is a veteran of drug discovery having led various oncology drugs from basic research through phase II clinical trials.
Prior to Tactic Pharmaceuticals, Dr. Mazar was Chief Scientific Officer at Attenuon, where he led the development of three drug projects from discovery into human clinical trials.He was also the Vice President of Biology at Ångstrom Pharmaceuticals, Inc., where he discovered the anti-angiogenic peptide Å6, which is currently being evaluated in phase II trials in oncology.He also discovered a novel uPA receptor-targeting peptide Å17, which was licensed to Diatide/Schering AG.
Prior to Ångstrom, Dr. Mazar spent over seven years at Abbott Laboratories, where he initiated two anti-angiogenesis pilot projects and was involved in the pre-clinicaldevelopment of two biologic agents that went through Phase III trials.
Dr. Mazar is also the co-inventor on twelve issued patents, forty pending patent applications, ninety-six full publications in refereed scientific journals, and eight book chapters including reviews on the uPA system, mouse tumor models and the therapeutic targeting of cancer.Dr. Mazar received his Ph.D. in Biochemistry from the University of Illinois College of Medicine.
Thank You for Downloading!
1. Download ZoomInfo Grow
2. Run Installation Wizard
3. Check your inbox to Sign in to ZoomInfo Grow